Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nuclear receptor 2C2-associated protein (NR2C2AP), also known as TRA16, is a nuclear protein encoded by the NR2C2AP gene. It acts as a corepressor of Testicular orphan nuclear receptor 4 (TR4, also called NR2C2) by binding to TR4 and selectively inhibiting its ability to bind DNA response elements and activate target gene transcription. NR2C2AP/TRA16 is predominantly localized in the nucleus, contains 139 amino acids (16 kDa), and shows specificity as a corepressor for TR4, exerting minimal effects on androgen, glucocorticoid, or progesterone receptor transactivation. Its function appears to be the selective repression of TR4-mediated activities, which potentially impact cell signaling in specific tissues, such as testis and possibly in cancer cell contexts. No drugs are directly known to target NR2C2AP, and it is not classified as a canonical therapeutic target.
Not a primary drug target; acts as a corepressor protein by inhibiting binding of TR4 (Testicular orphan nuclear receptor 4) to its DNA response element, thereby suppressing TR4-mediated transcriptional activation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nuclear receptor 2C2-associated protein (NR2C2AP).